Quantcast

Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins

January 2, 2014

JERUSALEM, January 2, 2014 /PRNewswire/ –

Oramed Pharmaceuticals Inc. [http://www.oramed.com ] (NASDAQCM: ORMP) (
http://www.oramed.com), a developer of oral drug delivery systems, announced today
that it has received Notices of Allowance from the Israel and Australian Patent Office
[http://www.ilpatsearch.justice.gov.il/UI/RequestDetails.aspx?ReqId=208165 ]s. The patent
entitled, “Methods and Compositions for Oral Administrations of Proteins” covers a core
concept of the company’s technology for the oral delivery of drugs and vaccines currently
delivered via injection. The allowance in Israel marks the second from the Israel Patent
Office in the past 30 days. Additionally, this is Oramed’s second Australian patent
allowance, following the grant of a different patent in May 2012. The patent has also been
approved in Japan, China, Russia, and New Zealand.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top
research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to
revolutionize the treatment of diabetes through its proprietary flagship product, an
orally ingestible insulin capsule (ORMD-0801 [http://oramed.com/index.php?page=14 ])
currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an
Investigational New Drug application with the U.S. Food and Drug Administration, and with
its oral exenatide capsule (ORMD-0901; a GLP-1 analog [http://oramed.com/index.php?page=14
]), with trials underway. Oramed is also moving forward with clinical trials of ORMD-0801
for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are
based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements.
For example, we are using forward-looking statements when we discuss our clinical trials
or revolutionizing the treatment of diabetes with our products. These forward-looking
statements and their implications are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product candidates; competition
from other pharmaceutical or biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in technology
and market requirements; delays or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and lack of
acceptance of our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients, all of which
could cause the actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to
time with the Securities and Exchange Commission.

        Company Contact:
        Oramed Pharmaceuticals
        Aviva Sherman
        Office: +972-2-566-0001
        Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


Source: PR Newswire



comments powered by Disqus